Prednisone
Based on 17 publication(s) in Google Scholar
Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.99%
- CAS No.: 53-03-2
- Formule: C21H26O5
- Masse moléculaire:358.43
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
Lipid Compound Library
HY-L043
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Endocrinology Compound Library
HY-L047
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Chemotherapy Drug Library
HY-L112
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Nuclear Receptor Compound Library
HY-L126
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Cysteine Targeted Covalent Library
HY-L153
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Steroid Hormones Library
HY-L239
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) Prednisone
More- Cell Metab. 2024 Nov 5;36(11):2402-2418.e10. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Cell Rep Med. 2025 Mar 24:102029. [Abstract]
- Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2117004119. [Abstract]
- Int J Biol Macromol. 2025 Jul 4;319(Pt 4):145753. [Abstract]
- Int J Biol Macromol. 2025 Jun 27:145620. [Abstract]
- Phytomedicine. 2023 Nov:120:155077. [Abstract]
- Clin Transl Med. 2025 May;15(5):e70336. [Abstract]
- Int Immunopharmacol. 2025 Jan 3:147:113964. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Immunopharmacol Immunotoxicol. 2025 Jul 30:1-11. [Abstract]
- Drug Test Anal. 2021 Feb;13(2):283-298. [Abstract]
- J Viral Hepat. 2026 Jan;33(1):e70118. [Abstract]
- Folia Histochem Cytobiol. 2024;62(2):110-121. [Abstract]
- SSRN. 2023 Nov 9.
- SSRN. 2023 Aug 3.
- SSRN. 2023 Feb 24.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IF
-
Bio/Physico-chemical Assay
-
IHC
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
>30 μM
Compound: Prednisone
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32422522] |
| FaDu | IC50 |
>30 μM
Compound: Prednisone
|
Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32422522] |
| HT-29 | IC50 |
>30 μM
Compound: Prednisone
|
Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32422522] |
| L1210 | ED50 |
>100 μM
Compound: Prednisone
|
Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
|
[PMID: 118258] |
| MCF7 | IC50 |
>30 μM
Compound: Prednisone
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32422522] |
| NIH3T3 | IC50 |
>30 μM
Compound: Prednisone
|
Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32422522] |
| REH | EC50 |
29 nM
Compound: Prednisone
|
Cytotoxicity against human REH cells overexpressing GR assessed as reduction in cell viability measured after 3 days by resazurin based assay
Cytotoxicity against human REH cells overexpressing GR assessed as reduction in cell viability measured after 3 days by resazurin based assay
|
[PMID: 34046609] |
Prednisone (5 mg/kg, intragastrically administration, daily) can cause changes in FA metabolism in SLE mouse (MRL/lpr) model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female MRL/lpr mice[3]
-
Dosage:5 mg/kg
-
Administration:intragastrically administration, daily
-
Result:Elevated polyunsaturated FA, such as arachidonic acid and docosahexaenoic acid, and reduced the total level of n-6 polyunsaturated fatty acidsin.
Chemical Information
-
CAS No. 53-03-2
-
Appearance Solid
-
Masse moléculaire 358.43
-
Formule C21H26O5
-
Color White to off-white
-
SMILES
C[C@@]1(C2)[C@](C(CO)=O)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3([H])C2=O)=O
-
Synonyms
Dehydrocortisone
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Sensing steroid hormone 17α-hydroxypregnenolone by GPR56 enables protection from ferroptosis-induced liver injury. [Abstract]2024 Nov 5;36(11):2402-2418.e10. PMID: 39389061 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cell Rep Med
A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities. [Abstract]2025 Mar 24:102029. PMID: 40147445 -
Proc Natl Acad Sci U S A
2022 Apr 12;119(15):e2117004119. PMID: 35394864 -
Int J Biol Macromol
Targeting local glucocorticoid metabolism with a silk fibroin microneedle for more effective hypertrophic scar repair. [Abstract]2025 Jul 4;319(Pt 4):145753. PMID: 40617420 -
Int J Biol Macromol
Integrative analysis using machine learning and RNA sequencing identifies TGFBI as a therapeutic target in HIV-associated osteonecrosis of the femoral head. [Abstract]2025 Jun 27:145620. PMID: 40582670 -
Phytomedicine
Cornuside improves murine autoimmune hepatitis through inhibition of inflammatory responses. [Abstract]2023 Nov:120:155077. PMID: 37716032
Prednisone purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155077. [Abstract]
Prednisone (0.5 mg/kg, intravenously as a single dose) decreased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels induced by Con A (18 mg/kg, iv as a single dose).
Prednisone purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155077. [Abstract]
Prednisone (0.5 mg/kg, intravenously as a single dose) reduced liver damage induced by Con A (18 mg/kg, iv as a single dose).
-
Clin Transl Med
IRF4 contributes to chemoresistance in IGH::BCL2-positive diffuse large B-cell lymphomas by mediating BCL2-induced SOX9 expression. [Abstract]2025 May;15(5):e70336. PMID: 40356256 -
Int Immunopharmacol
Cucurbitacin IIb mitigates concanavalin A-induced acute liver injury by suppressing M1 macrophage polarization. [Abstract]2025 Jan 3:147:113964. PMID: 39755110 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Immunopharmacol Immunotoxicol
Inhibition of long-lived plasma cells, a critical role for Telitacicept treatment to systemic lupus erythematosus. [Abstract]2025 Jul 30:1-11. PMID: 40734465
Prednisone purchased from MedChemExpress. Usage Cited in: Immunopharmacol Immunotoxicol. 2025 Jul 30:1-11. [Abstract]
Prednisone (5 mg/kg, gavage, once a day for 7 weeks) reduced proteinuria production in SLE mice at 4-5 weeks.
Prednisone purchased from MedChemExpress. Usage Cited in: Immunopharmacol Immunotoxicol. 2025 Jul 30:1-11. [Abstract]
Prednisone (5 mg/kg, gavage, once a day for 7 weeks) normalized spleen index scores in SLE mice.
Prednisone purchased from MedChemExpress. Usage Cited in: Immunopharmacol Immunotoxicol. 2025 Jul 30:1-11. [Abstract]
Prednisone (5 mg/kg, gavage, once a day for 7 weeks) did not significantly reduce C3 complement deposition in the kidneys of SLE mice.
-
Drug Test Anal
High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]2021 Feb;13(2):283-298. PMID: 32852861 -
J Viral Hepat
The Differential Effects of Immunosuppressants on Hepatitis E Virus Replication and the Triggered Inflammatory Responses in Macrophages. [Abstract]2026 Jan;33(1):e70118. PMID: 41400072 -
Folia Histochem Cytobiol
Dioscin attenuates lupus nephritis in NZB/W F1 mice by decreasing NF-κB activation and NLRP3 inflammasome. [Abstract]2024;62(2):110-121. PMID: 39042029 -
-
-
Solvant et solubilité
DMSO : 125 mg/mL (348.74 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (2.79 mM; ultrasonic and warming and heat to 80°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (422 KB)
- English - EN (422 KB)
- Français - FR (422 KB)
- Deutsch - DE (422 KB)
- Norwegian - NO (422 KB)
- Español - ES (422 KB)
- Swedish - SV (422 KB)
- Italian - IT (422 KB)
- Portuguese - PT (422 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. RIEMER AD. Application of the newer corticosteroids to augment diuresis in congestive heart failure. Am J Cardiol. 1958 Apr;1(4):488-96. [Content Brief]
[2]. [2]N Tomioka, et al. Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol. 1986 Apr;7(4):868-72. [Content Brief]
[3]. Qianqian Li, et al. Metabolic Profiling Reveals an Abnormal Pattern of Serum Fatty Acids in MRL/lpr Mice Under Treatment With Prednisone. Front Pharmacol. 2020 Feb 25;11:115. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.7899 mL | 13.9497 mL | 27.8995 mL | 69.7486 mL |
| DMSO | 5 mM | 0.5580 mL | 2.7899 mL | 5.5799 mL | 13.9497 mL |
| 10 mM | 0.2790 mL | 1.3950 mL | 2.7899 mL | 6.9749 mL | |
| 15 mM | 0.1860 mL | 0.9300 mL | 1.8600 mL | 4.6499 mL | |
| 20 mM | 0.1395 mL | 0.6975 mL | 1.3950 mL | 3.4874 mL | |
| 25 mM | 0.1116 mL | 0.5580 mL | 1.1160 mL | 2.7899 mL | |
| 30 mM | 0.0930 mL | 0.4650 mL | 0.9300 mL | 2.3250 mL | |
| 40 mM | 0.0697 mL | 0.3487 mL | 0.6975 mL | 1.7437 mL | |
| 50 mM | 0.0558 mL | 0.2790 mL | 0.5580 mL | 1.3950 mL | |
| 60 mM | 0.0465 mL | 0.2325 mL | 0.4650 mL | 1.1625 mL | |
| 80 mM | 0.0349 mL | 0.1744 mL | 0.3487 mL | 0.8719 mL | |
| 100 mM | 0.0279 mL | 0.1395 mL | 0.2790 mL | 0.6975 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz